Literature DB >> 7356361

Serum cefazolin levels during cardiopulmonary bypass.

B F Akl, G Richardson.   

Abstract

This study was done to assess the adequacy of a regimen using cefazolin as a prophylactic antibiotic for patients undergoing open-heart operation. At the time of the preoperative medication, adult patients received 1 gm of cefazolin intramuscularly, and pediatric patients were given a dose of 20 mg per kilogram of body weight. Group I consisted of 10 adults undergoing a variety of cardiac procedures. The mean serum cefazolin level after institution of cardiopulmonary bypass was 27.36 micrograms/ml (range, 13.1 to 40.3 micrograms/ml). This level remained fairly stable throughout cardiopulmonary bypass. Group II consisted of 10 pediatric patients undergoing cardiac procedures for repair of a variety of congenital anomalies. The mean serum cefazolin level after institution of cardiopulmonary bypass was 20.01 micrograms/ml (range, 11.4 to 28.9 micrograms/ml) and remained stable for the duration of the procedure. In both groups perfusion pressure, urinary output, and body temperature did not seem to have any influence on these levels. It is concluded that the administration of one dose of cefazolin intramuscularly before operation results in an adequate and stable serum cefazolin level in patients undergoing cardiopulmonary bypass for up to three hours, possibly longer.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7356361     DOI: 10.1016/s0003-4975(10)61646-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Perioperative antibiotic prophylaxis in cardiovascular surgery: a prospective randomized comparative trial of cefazolin versus ceftriaxone.

Authors:  M Soteriou; F Recker; S Geroulanos; M Turina
Journal:  World J Surg       Date:  1989 Nov-Dec       Impact factor: 3.352

2.  Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery.

Authors:  Megan H Nguyen; Samantha J Eells; Jennifer Tan; Corinne T Sheth; Bassam Omari; Margarita Flores; Jeffrey Wang; Loren G Miller
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

3.  Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition.

Authors:  R D Pryka; K A Rodvold; W Ting; S Levitsky; R W Frost; J T Lettieri
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 4.  Effect of cardiopulmonary bypass on the pharmacokinetics of drugs.

Authors:  F O Holley; K V Ponganis; D R Stanski
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

5.  Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double-blind trial in 1030 patients.

Authors:  A B Kaiser; M R Petracek; J W Lea; D S Kernodle; A C Roach; W C Alford; G R Burrus; D M Glassford; C S Thomas; W S Stoney
Journal:  Ann Surg       Date:  1987-12       Impact factor: 12.969

Review 6.  Cardiopulmonary bypass and the pharmacokinetics of drugs. An update.

Authors:  W A Buylaert; L L Herregods; E P Mortier; M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

7.  Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition.

Authors:  K J Klamerus; K A Rodvold; N A Silverman; S Levitsky
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.